Emergent Biosolutions

This study aims to collect information on how well the drug raxibacumab works and how safe it is for people with confirmed, serious anthrax infections. It will observe up to 10 patients in the US who receive the drug from the national stockpile as part of their standard medical c…

This study will evaluate the safety and effectiveness of a drug called AIGIV for treating people who develop inhalational anthrax after a major exposure event. It will only be activated if such a large-scale anthrax emergency occurs. Researchers will collect information on patien…

This study aims to collect real-world data on how well the drug raxibacumab works and how safe it is for treating people who develop symptomatic inhalational anthrax after a mass exposure event, such as a bioterror attack. It will enroll up to 100 patients of all ages who receive…

This study aims to learn about the safety and potential benefit of a treatment called AIGIV for people with severe, body-wide anthrax infections. It will collect information from up to 10 patients who receive this treatment as part of their standard medical care. The main goal is…

This study looks back at people who received the CYFENDUS anthrax vaccine after a mass exposure event. Researchers want to see how safe the vaccine was and if it helped prevent serious anthrax infections when given with antibiotics. The study will include about 250 people who got…